Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer
Immune checkpoint inhibitors (ICIs) have made great progress in the field of tumors and have become a promising direction of tumor treatment. With advancements in genomics and bioinformatics technology, it is possible to individually analyze the neoantigens produced by somatic mutations of each pati...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.689076/full |
| _version_ | 1818974066844893184 |
|---|---|
| author | Xue-lin Zou Xiao-bo Li Hua Ke Guang-yan Zhang Qing Tang Jiao Yuan Chen-jiao Zhou Ji-liang Zhang Rui Zhang Wei-yong Chen |
| author_facet | Xue-lin Zou Xiao-bo Li Hua Ke Guang-yan Zhang Qing Tang Jiao Yuan Chen-jiao Zhou Ji-liang Zhang Rui Zhang Wei-yong Chen |
| author_sort | Xue-lin Zou |
| collection | DOAJ |
| description | Immune checkpoint inhibitors (ICIs) have made great progress in the field of tumors and have become a promising direction of tumor treatment. With advancements in genomics and bioinformatics technology, it is possible to individually analyze the neoantigens produced by somatic mutations of each patient. Neoantigen load (NAL), a promising biomarker for predicting the efficacy of ICIs, has been extensively studied. This article reviews the research progress on NAL as a biomarker for predicting the anti-tumor effects of ICI. First, we provide a definition of NAL, and summarize the detection methods, and their relationship with tumor mutation burden. In addition, we describe the common genomic sources of NAL. Finally, we review the predictive value of NAL as a tumor prediction marker based on various clinical studies. This review focuses on the predictive ability of NAL’s ICI efficacy against tumors. In melanoma, lung cancer, and gynecological tumors, NAL can be considered a predictor of treatment efficacy. In contrast, the use of NAL for urinary system and liver tumors requires further research. When NAL alone is insufficient to predict efficacy, its combination with other indicators can improve prediction efficiency. Evaluating the response of predictive biomarkers before the treatment initiation is essential for guiding the clinical treatment of cancer. The predictive power of NAL has great potential; however, it needs to be based on more accurate sequencing platforms and technologies. |
| first_indexed | 2024-12-20T15:34:09Z |
| format | Article |
| id | doaj.art-b16a038557174d2a8931af2f50fe2d3b |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-20T15:34:09Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-b16a038557174d2a8931af2f50fe2d3b2022-12-21T19:35:31ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-12-011210.3389/fimmu.2021.689076689076Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for CancerXue-lin Zou0Xiao-bo Li1Hua Ke2Guang-yan Zhang3Qing Tang4Jiao Yuan5Chen-jiao Zhou6Ji-liang Zhang7Rui Zhang8Wei-yong Chen9Department of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Oncology, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Thoracic Surgery, Chengdu Seventh People’s Hospital, Chengdu, ChinaDepartment of Respiratory Medicine, Chengdu Seventh People’s Hospital, Chengdu, ChinaImmune checkpoint inhibitors (ICIs) have made great progress in the field of tumors and have become a promising direction of tumor treatment. With advancements in genomics and bioinformatics technology, it is possible to individually analyze the neoantigens produced by somatic mutations of each patient. Neoantigen load (NAL), a promising biomarker for predicting the efficacy of ICIs, has been extensively studied. This article reviews the research progress on NAL as a biomarker for predicting the anti-tumor effects of ICI. First, we provide a definition of NAL, and summarize the detection methods, and their relationship with tumor mutation burden. In addition, we describe the common genomic sources of NAL. Finally, we review the predictive value of NAL as a tumor prediction marker based on various clinical studies. This review focuses on the predictive ability of NAL’s ICI efficacy against tumors. In melanoma, lung cancer, and gynecological tumors, NAL can be considered a predictor of treatment efficacy. In contrast, the use of NAL for urinary system and liver tumors requires further research. When NAL alone is insufficient to predict efficacy, its combination with other indicators can improve prediction efficiency. Evaluating the response of predictive biomarkers before the treatment initiation is essential for guiding the clinical treatment of cancer. The predictive power of NAL has great potential; however, it needs to be based on more accurate sequencing platforms and technologies.https://www.frontiersin.org/articles/10.3389/fimmu.2021.689076/fullcancerneoantigen loadimmune checkpoint inhibitorbiomarkerprognostic value |
| spellingShingle | Xue-lin Zou Xiao-bo Li Hua Ke Guang-yan Zhang Qing Tang Jiao Yuan Chen-jiao Zhou Ji-liang Zhang Rui Zhang Wei-yong Chen Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer Frontiers in Immunology cancer neoantigen load immune checkpoint inhibitor biomarker prognostic value |
| title | Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer |
| title_full | Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer |
| title_fullStr | Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer |
| title_full_unstemmed | Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer |
| title_short | Prognostic Value of Neoantigen Load in Immune Checkpoint Inhibitor Therapy for Cancer |
| title_sort | prognostic value of neoantigen load in immune checkpoint inhibitor therapy for cancer |
| topic | cancer neoantigen load immune checkpoint inhibitor biomarker prognostic value |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.689076/full |
| work_keys_str_mv | AT xuelinzou prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT xiaoboli prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT huake prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT guangyanzhang prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT qingtang prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT jiaoyuan prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT chenjiaozhou prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT jiliangzhang prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT ruizhang prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer AT weiyongchen prognosticvalueofneoantigenloadinimmunecheckpointinhibitortherapyforcancer |